drugset / Trial / NCT01288079

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079

Phase 2 Terminated 145 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.

Timeline

Start
2011-02
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Subject dexmecamylamine Other / unclassified 1 mg Oral
Subject dexmecamylamine Other / unclassified 4 mg Oral